CompletedPhase 3NCT04494438

Rituximab for Idiopathic Nephrotic Syndrome

Studying Idiopathic nephrotic syndrome

Last synced from ClinicalTrials.gov April 1, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Istituto Giannina Gaslini
Principal Investigator: Gian Marco Ghiggeri, MD
Istituto Giannina Gaslini
Intervention: Rituximab(drug)
Enrollment: 30 target
Eligibility: 1-16 years · All sexes
Timeline: 2013 – 2016

Study locations (1)

IRCCS Giannina Gaslini Institute, Genova, Italy

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT04494438 on ClinicalTrials.gov

Other trials for Idiopathic nephrotic syndrome

Additional recruiting or active studies for the same condition.

RECRUITINGNCT06820866
Non-invasive Diagnosis of Idiopathic Nephrotic Syndromes
Assistance Publique - Hôpitaux de Paris
ACTIVE NOT RECRUITINGPHASE3NCT05627557
A Study to Evaluate the Efficacy and Safety of Obinutuzumab Versus MMF in Participants With Childhood Onset Idiopathic Nephrotic Syndrome
Hoffmann-La Roche
RECRUITINGNCT04207580
A National Prospective Cohort of Patients With Idiopathic Nephrotic Syndrome Beginning in Childhood.
University Hospital, Limoges

See all trials for Idiopathic nephrotic syndrome →

← Back to all trials